CAJ | 학술논문

目的：观察盐酸埃克替尼治疗晚期非小细胞肺癌（NSCLC）患者的疗效和安全性。方法126例Ⅲb~Ⅳ期NSCLC患者接受盐酸埃克替尼治疗，直至PD或出现不能耐受的重度毒副反应而终止治疗，并以93例接受吉非替尼治疗的Ⅲb~Ⅳ期NSCLC患者作为对照，评价2种药物的疗效和毒副反应。结果盐酸埃克替尼组饮食及睡眠质量改善率为53.2％，高于吉非替尼组的37.6％（P＜0.05）。盐酸埃克替尼组有效率为46.0％，吉非替尼组为45.2％（P＞0.05）；盐酸埃克替尼组疾病控制率为86.5％，高于吉非替尼组的74.2％（P＜0.05）。2组主要毒副反应均为皮疹、腹泻，发生率相近（P＞0.05）。结论盐酸埃克替尼在晚期NSCLC的治疗中与吉非替尼近期疗效和安全性相近，但均稍有优势。
목적：관찰염산애극체니치료만기비소세포폐암（NSCLC）환자적료효화안전성。방법126례Ⅲb~Ⅳ기NSCLC환자접수염산애극체니치료，직지PD혹출현불능내수적중도독부반응이종지치료，병이93례접수길비체니치료적Ⅲb~Ⅳ기NSCLC환자작위대조，평개2충약물적료효화독부반응。결과염산애극체니조음식급수면질량개선솔위53.2％，고우길비체니조적37.6％（P＜0.05）。염산애극체니조유효솔위46.0％，길비체니조위45.2％（P＞0.05）；염산애극체니조질병공제솔위86.5％，고우길비체니조적74.2％（P＜0.05）。2조주요독부반응균위피진、복사，발생솔상근（P＞0.05）。결론염산애극체니재만기NSCLC적치료중여길비체니근기료효화안전성상근，단균초유우세。
Objective Toobservethecurativeeffectandsafetyoficotinibhydrochlorideinthetreatmentofnon-smallcelllungcancer(NSCLC).Methods 126patientswithNSCLC(stageⅢb-Ⅳ)weregivenicotinibhydro-chloride until the PD or the presence of intolerant severe adverse reaction. With gefitinib as the control(93 patients withNSCLC),thecurativeeffectandtoxicitiesoficotinibhydrochloridewereevaluated.Results Thedietand sleep period improvement rate of the icotinib hydrochloride group was 53. 2%,and was 37. 6% of the gefitinib group (P>0. 05). The effective rate of the icotinib hydrochloride group was 46. 0%,and was 45. 2% of the gefitinib group(P>0. 05). The effective rate of the icotinib hydrochloride group was 86. 5%,and was 74. 2% of the ge-fitinib group(P<0. 05).Ⅰn the two groups,the main toxicities were rash and diarrhea,the incidence of the icotinib hydrochloridegroupwassimilartothatofthegefitinibgroup(P>0.05).Conclusion Ⅰcotinibhydrochloridehas similar curative effects and toxicities as gefitinib in the treatment of advanced NSCLC.